[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Ryu HJ, Hahn JS, Kim YS, Park K, Yang WI, Lee JD: Complete resolution of posttransplant lymphoproliferative disorder (diffuse large B-cell lymphoma) with reduction of immunosuppressive therapy. Yonsei Med J; 2004 Jun 30;45(3):527-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete resolution of posttransplant lymphoproliferative disorder (diffuse large B-cell lymphoma) with reduction of immunosuppressive therapy.
  • Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation.
  • PTLD is the disorder arising from the combined effects of Epstein-Barr virus associated lymphoid proliferation with the disruption of the normal immune control by the cytotoxic T cells.
  • The treatment for PTLD is one of the most controversial topics in solid organ transplantation.
  • It is well known that the initial management of PTLD is a reduction of immunosuppression.
  • Early diagnosis and the early reduction in immunosuppression are essential even for monomorphic lymphoma.
  • We report here on a case of the complete resolution of PTLD (diffuse large B cell lymphoma) which occurred after a drastic reduction of immunosuppression in a renal transplant recipient.
  • [MeSH-major] Graft Rejection / drug therapy. Immunosuppressive Agents / administration & dosage. Kidney Transplantation. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Humans. Korea. Male. Remission Induction. Tomography, Emission-Computed. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15227742.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


2. Makhdoomi K, Ghaffari Moghaddam A, Aishi Oskue A, Mohammadi A, Ilkhanizadeh B, Enshae A, Shateri K, Esmaeli A: Extranodal diffuse large B-cell lymphoma confined to liver in a kidney transplant recipient. Iran J Kidney Dis; 2010 Oct;4(4):336-9
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal diffuse large B-cell lymphoma confined to liver in a kidney transplant recipient.
  • Posttransplant lymphoproliferative disorder (PTLD) is a well-documented complication that arises as a result of immunosuppression in the setting of solid organ or bone marrow transplantation.
  • The disorder may be subtle and/or extranodal.
  • We report a patient with extranodal lymphoma following kidney transplantation who had successful treatment with surgery and chemotherapy.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoma, Large B-Cell, Diffuse / etiology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Liver Transplant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20852378.001).
  • [ISSN] 1735-8582
  • [Journal-full-title] Iranian journal of kidney diseases
  • [ISO-abbreviation] Iran J Kidney Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


3. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Váry M, Babel N, Trappe RU, Jonas S, Hummel M, Anagnostopoulos I, Dörken B, Riess HB: Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant; 2005 Dec;5(12):2901-6
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).
  • Post-transplant lymphoproliferative disorders (PTLD) are a life-threatening complication following solid organ transplantation.
  • Treatment with rituximab, a humanized anti-CD20 monoclonal antibody, has proved to be a promising approach and shown a low toxicity profile.
  • Between February 1999 and April 2002, we conducted a multicentre phase II trial investigating rituximab as single agent in 17 patients with PTLD.
  • The mean follow-up time is 24.2 months.
  • Histology was distributed in 10 diffuse large cell-, 2 marginal zone-, 1 Burkitt-like lymphoma, 1 Hodgkin-like PTLD and 3 polymorphic lymphoproliferations.
  • Therapy was well tolerated and no severe adverse events were observed.
  • Rituximab proved to be well tolerated and effective in the treatment of PTLD.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / immunology. Antineoplastic Agents / administration & dosage. Lymphoproliferative Disorders / drug therapy. Transplants
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Heart Transplantation. Humans. Kidney Transplantation. Liver Transplantation. Lung Transplantation. Male. Middle Aged. Postoperative Complications / drug therapy. Postoperative Complications / immunology. Postoperative Complications / mortality. Prognosis. Prospective Studies. Rituximab. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303003.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


Advertisement
4. Sudheendra D, Barth MM, Hegde U, Wilson WH, Wood BJ: Radiofrequency ablation of lymphoma. Blood; 2006 Feb 15;107(4):1624-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of lymphoma.
  • Percutaneous minimally invasive radiofrequency (RF) ablation has not been described for lymphoma.
  • This image-guided modality is presented in 3 different settings for the treatment of refractory lymphoma.
  • The first patient received RF ablation for the curative treatment of a solitary residual hepatic mass following rituximab-based chemotherapy for a posttransplantation lymphoproliferative disorder (PTLD) and is disease-free 4 years later.
  • The second patient received RF ablation for successful palliation of progressive follicular lymphoma adjacent to the bladder wall following chemotherapy and maximum radiation.
  • The third patient received RF ablation for prevention of airway obstruction from progressive diffuse large B-cell lymphoma of the right neck following chemotherapy and maximum radiation.
  • RF ablation may be clinically beneficial and should be considered for the treatment of local lymphoma that is refractory or not amenable to standard approaches.
  • [MeSH-major] Lymphoma, B-Cell / radiotherapy. Radio Waves / therapeutic use
  • [MeSH-minor] Adult. Humans. Kidney Transplantation. Male. Middle Aged. Postoperative Complications. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hyperthermia. 2004 Nov;20(7):781-802 [15675672.001]
  • [Cites] Surg Oncol. 2005 Jul;14(1):41-52 [15777889.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):51-7 [15972398.001]
  • [Cites] Tech Vasc Interv Radiol. 2002 Sep;5(3):156-63 [12524646.001]
  • [Cites] Eur J Ultrasound. 2001 Jun;13(2):129-47 [11369525.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):41-7 [11842388.001]
  • [Cites] J Chemother. 2004 Nov;16 Suppl 5:86-9 [15675488.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1110-4 [12163638.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Mar;9(3):162-9 [12652466.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6496-500 [14559842.001]
  • [Cites] Radiology. 2004 Jan;230(1):169-74 [14645878.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4024-9 [15173017.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2685-93 [11929754.001]
  • (PMID = 16254135.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CL999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1895403
  •  go-up   go-down


5. Chia SC, Chau YP, Tan YM: Late-onset post-transplant lymphoproliferative disease presenting as massive occult gastrointestinal haemorrhage. Singapore Med J; 2008 May;49(5):e117-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset post-transplant lymphoproliferative disease presenting as massive occult gastrointestinal haemorrhage.
  • Post-transplant lymphoproliferative disease (PTLD) is a widely-recognised complication of solid organ transplants with a myriad of clinical presentations.
  • We report a 56-year-old Chinese woman who developed PTLD 17 years after a renal transplant.
  • She initially presented with constitutional symptoms, and a diagnosis of diffuse large B-cell lymphoma was confirmed on liver biopsy.
  • Staging computed tomography demonstrated widespread adenopathy.
  • Initial treatment consisted of reduction of immunosuppression and Rituximab.
  • Prior to institution of chemotherapy, she presented with life-threatening melaena.
  • Histology confirmed necrotic diffuse large B-cell lymphoma and the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regime was subsequently commenced.
  • The aim of this case report is to highlight the unique challenges in the management of PTLD in the context of an acute abdomen.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Jejunal Neoplasms / diagnosis. Kidney Transplantation. Lymphoma, Large B-Cell, Diffuse / diagnosis. Postoperative Complications


6. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA: Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer; 2005 Oct 15;104(8):1661-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
  • BACKGROUND: Posttransplant lymphoproliferative disorders (PTLD) remain an uncommon complication of solid organ transplantation with a high mortality rate reported after conventional therapies.
  • Alternative treatments such as rituximab have been explored.
  • METHODS: Eleven patients with PTLD, who were CD20 positive, received an intravenous dose of rituximab, 375 mg/m2, weekly x 4 weeks, repeated every 6 months for 2 years in responding patients.
  • The type of solid organ transplantation that these patients received included lung (five patients), kidney (four patients), heart (one patient), and kidney/pancreas (one patient).
  • The median time from transplantation to a PTLD diagnosis was 9 months (range, 1-122 mos).
  • Diagnostic B-cell histology was diffuse large cell lymphoma or polymorphous process.
  • Immunosuppressive therapy was decreased at the time of diagnosis.
  • The median time to treatment failure was 10 months (range, 5-25+ mos).
  • Four patients were alive at the time of last follow-up.
  • CONCLUSIONS: Single-agent rituximab may offer a response and survival advantage in patients with PTLD.
  • Further evaluation of rituximab in these disorders, potentially in combination with other therapies, is warranted.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Organ Transplantation / adverse effects. Postoperative Complications / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Prognosis. Rituximab. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16149091.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 40
  •  go-up   go-down


7. Kusuki S, Hashii Y, Fukushima N, Takizawa S, Tokimasa S, Kogaki S, Ohta H, Tsuda E, Nakagawa A, Ozono K: Pediatric post-transplant diffuse large B cell lymphoma after cardiac transplantation. Int J Hematol; 2009 Mar;89(2):209-13
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric post-transplant diffuse large B cell lymphoma after cardiac transplantation.
  • Post-transplant lymphoproliferative disorders (PTLDs) occur in 3.5-9% of patients after pediatric cardiac transplantation.
  • Caution is needed when treating patients with PTLD because of the risk of allograft rejection frequently caused by withdrawal of immunosuppression.
  • In this report, we describe a 47-month-old boy who developed PTLD as an ileocecal mass 29 months after cardiac transplantation.
  • Immunosuppressive therapy with cyclosporine A (CyA) had been reduced due to an elevation of Epstein-Barr virus (EBV) titer for 8 months before development of PTLD.
  • Histology of the tumor was diffuse large B cell lymphoma.
  • He was treated with rituximab and combination chemotherapy with excellent response.
  • CyA dose was maintained at reduced levels during chemotherapy and later minimized with introduction of everolimus.
  • The child is free of both PTLD and allograft rejection 41 months after the diagnosis of PTLD.
  • [MeSH-major] Cyclosporine / adverse effects. Heart Transplantation / adverse effects. Lymphoma, Large B-Cell, Diffuse / chemically induced
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytogenetic Analysis. Herpesvirus 4, Human / isolation & purification. Humans. Infant. Male. Rituximab

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Transplant. 2006 Feb;10(1):60-6 [16499589.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1057-63 [1671647.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Med Oncol. 2007;24(2):125-36 [17848735.001]
  • [Cites] Transplantation. 2004 Dec 15;78(11):1676-82 [15591959.001]
  • [Cites] Pediatr Transplant. 2009 Feb;13(1):54-62 [18518912.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jan;23(1):14-8 [11196263.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] Lancet. 2006 Jan 21;367(9506):233-9 [16427492.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5595-610 [11607812.001]
  • [Cites] Pediatr Transplant. 2007 Feb;11(1):58-65 [17239124.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]
  • (PMID = 19156500.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


8. Godt C, Regnery A, Schwarze B, Junker K, Porschen R: A rare cause of ulcerative colitis - diarrhoea and perianal bleeding due to posttransplant lymphoproliferative disorder (PTLD). Z Gastroenterol; 2009 Mar;47(3):283-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare cause of ulcerative colitis - diarrhoea and perianal bleeding due to posttransplant lymphoproliferative disorder (PTLD).
  • Post-transplant lymphoproliferative disorder (PTLD) is characterised by frequent extranodal manifestation, in 20 - 25 % including the gastrointestinal tract.
  • He had received a bone marrow transplant two years previously for an acute lymphocytic leukaemia of B-cell origin.
  • Further investigations revealed a diffuse infiltration of the liver, spleen, both kidneys and lungs.
  • Histologically, a monomorphic post-transplant lymphoproliferative disorder was diagnosed, the subtype was a high grade diffuse-large cell Non-Hodgkin's lymphoma of B-cell origin.
  • This is a common feature of PTLD and possibly plays a critical role in its pathogenesis.
  • The current therapeutic approach to the subtype of PTLD we saw in this patient is CHOP chemotherapy, comprising the anti-CD 20 antibody rituximab if CD 20-positivity is present.
  • This patient had a fatal course of the disease and died a few days after the first chemotherapy cycle due to severe multiple organ failure.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Colitis, Ulcerative / etiology. Colorectal Neoplasms / diagnosis. Diarrhea / etiology. Gastrointestinal Hemorrhage / etiology. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


9. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M: Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol; 2005 Nov;20(11):1660-3
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.
  • A 12-year-old Japanese boy who underwent kidney transplantation with a kidney from his mother developed severe proteinuria immediately after the operation.
  • Four months after the transplantation, posttransplant lymphoproliferative disorder (PTLD) developed, which was pathologically diagnosed as diffuse large B cell lymphoma.
  • Treatment consisting of a reduction in immunosuppression resulted in improvement in PTLD a month after the start of treatment.
  • However, relapse occurred 2 months after the first onset of PTLD, which we treated with rituximab (CD-20 monoclonal antibody 375 mg/m2) once weekly for a total of four doses.
  • The PTLD resolved immediately after the rituximab treatment was started, and, interestingly, urinary protein levels also improved at the same time.
  • Three years later, the boy shows no signs of PTLD, and no proteinuria has been detected.
  • These findings suggest that rituximab may be an effective treatment for recurrence of nephrotic syndrome after transplantation and that activated B cells may play a pivotal role in the recurrence of nephrosis after renal transplantation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Kidney Transplantation. Lymphoma, B-Cell / drug therapy. Nephrotic Syndrome / complications

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Nephrol. 2007 Jan;22(1):158-60 [16937130.001]
  • [Cites] J Am Soc Nephrol. 1992 Jun;2(12 Suppl):S258-63 [1498285.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):501-13 [15693003.001]
  • [Cites] Am J Med. 1992 Apr;92(4):375-83 [1558084.001]
  • [Cites] Pediatr Nephrol. 2004 Jul;19(7):794-7 [15071769.001]
  • [Cites] J Am Soc Nephrol. 1998 Sep;9(9):1709-15 [9727380.001]
  • [Cites] J Am Soc Nephrol. 1999 Sep;10(9):2014-7 [10477155.001]
  • [Cites] Pediatr Nephrol. 1994 Feb;8(1):94-5 [8142240.001]
  • [Cites] Transplantation. 1999 Nov 27;68(10):1517-25 [10589949.001]
  • [Cites] Clin Nephrol. 2003 Oct;60(4):242-7 [14579938.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):456-61 [12139732.001]
  • [Cites] J Am Soc Nephrol. 2003 Jul;14(7):1851-7 [12819245.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1076-88 [11374406.001]
  • [Cites] Lancet. 1999 Nov 13;354(9191):1698-9 [10568575.001]
  • [Cites] Intern Med. 2003 Jan;42(1):98-101 [12583628.001]
  • [Cites] Transplant Proc. 2002 May;34(3):955-6 [12034258.001]
  • [Cites] Nephrol Dial Transplant. 2002;17 Suppl 4:16-8 [12091621.001]
  • [Cites] N Engl J Med. 1996 Apr 4;334(14):878-83 [8596570.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):112-8 [11722420.001]
  • [Cites] Kidney Int. 1991 Sep;40(3):453-60 [1787645.001]
  • [Cites] Transplantation. 2000 Feb 15;69(3):430-2 [10706055.001]
  • [Cites] J Am Soc Nephrol. 1992 Jun;2(12 Suppl):S255-7 [1498284.001]
  • [Cites] Clin Transplant. 1994 Dec;8(6):546-9 [7865917.001]
  • [Cites] Nephron. 1983;35(4):225-31 [6358923.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Apr;34(4):389-93 [11930095.001]
  • [Cites] Am J Kidney Dis. 2004 Jul;44(1):50-6 [15211437.001]
  • (PMID = 16133051.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


10. Bhargava R, Barbashina V, Filippa DA, Teruya-Feldstein J: Epstein-Barr virus positive large B-cell lymphoma arising in a patient previously treated with Cladribine for hairy cell leukemia. Leuk Lymphoma; 2004 May;45(5):1043-8
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus positive large B-cell lymphoma arising in a patient previously treated with Cladribine for hairy cell leukemia.
  • We describe the case of a patient treated with 2-chloro-2'-deoxyadenosine, CdA or Cladribine for hairy cell leukemia who subsequently developed an Epstein Barr virus (EBV)-positive polymorphous large B-cell lymphoma (p-LBCL).
  • The time interval between Cladribine therapy and development of p-BCL was 11 months and morphologically resembled an EBV-positive post transplant lymphoproliferative disorder (PTLD).
  • Unlike most methotrexate-related lymphoproliferative disorders (LPDs), which undergo spontaneous remission after discontinuation of therapy, LPDs secondary to purine analogs often fails to resolve after discontinuation of therapy and requires additional therapy.
  • Our patient was treated with rituximab following the diagnosis of p-LBCL, with the goal of improving the pancytopenia to permit chemotherapy.
  • However, the patient failed to show any dramatic improvements in counts, developed systemic symptoms and progressive ascites.
  • Cladribine is a potent immunosuppressive agent and should be included with the list of immunosuppressive agents that may be associated with EBV-related B-cell lymphoproliferative disorders.
  • [MeSH-major] Cladribine / adverse effects. Herpesvirus 4, Human. Leukemia, Hairy Cell / complications. Lymphoma, Large B-Cell, Diffuse / chemically induced. Lymphoma, Large B-Cell, Diffuse / virology

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15291365.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 47M74X9YT5 / Cladribine
  •  go-up   go-down


11. Tajika K, Tamai H, Mizuki T, Nakayama K, Yamaguchi H, Dan K: [Epstein-Barr virus-related B-cell lymphoma of the skin which developed early after cord blood transplantation for angioimmunoblastic T-cell lymphoma]. Rinsho Ketsueki; 2010 Feb;51(2):138-42
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr virus-related B-cell lymphoma of the skin which developed early after cord blood transplantation for angioimmunoblastic T-cell lymphoma].
  • We report here a rare case of EBV-related post-transplantation lymphoproliferative disorder (PTLD) localized to the skin.
  • The patient was a 64-year-old man diagnosed with angioimmunoblastic T cell lymphoma (AITL).
  • He underwent cord blood transplantation with a reduced intensity conditioning regimen during partial remission after chemotherapy.
  • On day 70 after transplantation, subcutaneous tumors developed near the left scapula and in the left upper arm.
  • Pathological examination of the skin tumor revealed that this tumor was composed of diffuse large centroblast-like cells, the majority of which were CD20 positive, CD 79a positive, CD30 positive and Epstein-Barr virus (EBV) latency-associated RNA (EBER) positive, and EBV-DNA was also detected in tumor cells.
  • At that time, real-time polymerase chain reaction documented no evidence of the EBV genome in his blood.
  • Chimerism analysis revealed that the tumor cells were derived from donor cells, which led to the diagnosis of EBV-related PTLD.
  • For treatment, in addition to decreasing the dose of tacrolimus, we administered rituximab and local irradiation to skin lesions, which led to disappearance of the tumors followed by continued complete remission.
  • [MeSH-major] Fetal Blood / transplantation. Herpesvirus 4, Human. Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy. Lymphoproliferative Disorders / virology. Skin Diseases / virology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Humans. Male. Middle Aged. Remission Induction. Rituximab. Tissue Donors. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379106.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


12. Kudo K, Sonoda M, Sugimoto K, Koike M: [Cutaneous non-Hodgkin lymphoma of the leg occurring 11 years after renal transplantation]. Rinsho Ketsueki; 2009 Feb;50(2):107-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous non-Hodgkin lymphoma of the leg occurring 11 years after renal transplantation].
  • She received immunosuppressive therapy postoperatively.
  • Skin lesion was recognized on the left leg in April 2002 and skin biopsy demonstrated diffuse large B cell lymphoma in March 2006.
  • EBV-LMP, EBNA-2 and EBER were positive and she was diagnosed as having EBV-related posttransplant lymphoproliferative disease (PTLD).
  • Radiation therapy and rituximab therapy were administered.
  • We reduced the dose of immunosuppressive drug and performed debridement of the ulcer, which responded well to treatment.
  • PTLD presenting with skin involvement rarely manifests as lesions, and such lesions develop slowly, when they occur.
  • PTLD presenting with skin involvement after transplantation must be treated.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Kidney Transplantation / adverse effects. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoproliferative Disorders / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Debridement. Female. Humans. Immunosuppressive Agents / administration & dosage. Middle Aged. Polycystic Kidney Diseases / surgery. Time Factors


13. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW: Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol; 2009 Jul 10;27(20):3354-62
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
  • PURPOSE: We studied the incidence, risk factors, treatment, and outcomes of post-transplantation lymphoproliferative disorder (PTLD) that occurred at the University of Michigan since 1964.
  • PATIENTS AND METHODS: We identified 7,040 patients who received solid organ transplantation (SOT) and post-transplantation immunosuppressive therapy.
  • Seventy-eight patients developed PTLD.
  • RESULTS: Diffuse large B-cell lymphoma (n = 43), polymorphic PTLD (n = 10), Hodgkin's lymphoma (n = 7), Burkitts lymphoma (n = 6), plasmacytoma (n = 5), and mucosa-associated lymphoid tissue lymphoma (n = 3) were all over-represented in the SOT population compared with a population sample from the Surveillance, Epidemiology, and End Results (SEER) database; follicular lymphoma (n = 0) was underrepresented.
  • Negative pretransplantation Epstein-Barr virus (EBV) serology was a risk factor for PTLD.
  • Available histologic analysis of tumor tissue showed that 75% were CD20 positive and that 62% were EBV positive; EBV-positive tumors occurred sooner after SOT than EBV-negative tumors (mean, 29 v 66 months).
  • Extralymphatic disease (79%), poor performance status (68%), elevated lactate dehydrogenase (LDH; 71%), and advanced stage (68%) disease were all common at the time of lymphoma diagnosis.
  • Two thirds of patients had a complete response when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone-like chemotherapy (either with or without rituximab).
  • Median overall survival in all patients with PTLD was 8.23 years (95% CI, 2.28 to 30.0 years).
  • CONCLUSION: EBV-naïve patients who receive a donor organ from an EBV-infected donor are in the highest-risk situation for PTLD development.
  • Follicular lymphoma is unusual.
  • With treatment, survival of patients with PTLD was indistinguishable from that of the SEER population sample.
  • [MeSH-major] Lymphoma / etiology. Lymphoproliferative Disorders / etiology. Organ Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / metabolism. Humans. Immunohistochemistry. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. In Situ Hybridization. Kaplan-Meier Estimate. Male. Michigan. Middle Aged. RNA, Viral / genetics. Risk Factors. Tacrolimus / adverse effects. Tacrolimus / therapeutic use. Treatment Outcome. Viral Matrix Proteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Immunosuppressive Agents; 0 / RNA, Viral; 0 / Viral Matrix Proteins; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


14. Bobey NA, Stewart DA, Woodman RC: Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by autologous peripheral blood stem cell transplantation. Leuk Lymphoma; 2002 Dec;43(12):2421-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant patient by autologous peripheral blood stem cell transplantation.
  • Posttransplant lymphoproliferative disorder (PTLD), a well recognized complication of organ transplantation, comprises a wide spectrum of heterogeneous lymphoid proliferations ranging from self-limiting mononucleosis through aggressive monoclonal non-Hodgkin's lymphoma (NHL).
  • There has been marginal success in treating PTLD using a number of treatment modalities, including combination chemotherapy.
  • There have been few reports of the use of high dose chemotherapy with stem cell rescue as a treatment for PTLD.
  • We report a renal allograft recipient who developed PTLD of the diffuse large cleaved B cell, NHL type.
  • Reduction of immunosuppression was initially effective, however the patient relapsed, and was treated successfully with CHOP chemotherapy.
  • Two years later he again relapsed and was treated with high dose melphalan followed by autologous peripheral blood stem cell transplantation (PSCT).
  • This case illustrates a potential role for high dose chemotherapy with stem cell transplantation for the treatment of PTLD.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Humans. Immunosuppression / adverse effects. Lymphoma, B-Cell / etiology. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, Large B-Cell, Diffuse / therapy. Male. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613536.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Taj MM, Messahel B, Mycroft J, Pritchard-Jones K, Baker A, Height S, Hadzic N, Pinkerton CR: Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. Br J Haematol; 2008 Jan;140(2):191-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children.
  • Childhood post-transplant lymphoproliferative disease (PTLD) is a heterogeneous condition in which treatment varies, from the reduction of immunosuppression to moderately intensive chemotherapy.
  • While low-dose chemotherapy/rituximab has been found to be effective, moderately intensive chemotherapy is required for patients who relapse, have classic non-Hodgkin lymphoma or have fulminant PTLD.
  • However, there are no data in the literature regarding its safety in post-liver transplant patients.
  • We describe four cases of high-grade lymphomas (three diffuse large B cell and one T-cell lymphoblastic), post-liver transplant, for which chemotherapy including high-dose Mtx (HDMTX) was the treatment of choice.
  • The treatment was well tolerated and all four patients had a good response.
  • One case of central nervous system (CNS) diffuse large B-cell lymphoma was treated with HDMTX alone.
  • We conclude that, in the absence of significant organ damage, HDMTX can safely be given to liver transplant patients, but should only be administered in specialist oncology units.
  • Proof of effectiveness as a single agent in CNS lymphoma needs further studies.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Central Nervous System Neoplasms / drug therapy. Liver Transplantation. Lymphoma, Non-Hodgkin / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Child. Child, Preschool. Drug-Induced Liver Injury. Humans. Male. Postoperative Complications / drug therapy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18173755.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


16. Sandrini S, Valerio F, Insalaco M: [Kidney transplantation and lymphomas]. G Ital Nefrol; 2010 Sep-Oct;27 Suppl 50:S46-50
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Post-transplant lymphoproliferative disease (PTLD) accounts for 30% of nonskin cancers after kidney transplants.
  • Diffuse large B-cell lymphoma is the most frequent form of PTLD.
  • The incidence of PTLD increases over time: from 1.2% at 5 years to 6.8% at 20 years.
  • Moreover, not only is it more frequent but also more serious than the early type because of the lower responsiveness to therapy.
  • During the first year after transplant, EBV-PCR monitoring can be helpful for the early diagnosis of EBV-associated PTLD, especially in children.
  • No effective strategy has yet been reported for the prevention of late PTLD.
  • Interruption of immunosuppression is the first step of therapy, but it is rarely effective by itself.
  • Chemotherapy becomes essential in relapsed or refractory disease, but it significantly increases the risk of life-threatening infections.
  • The mortality rate is around 50% 12 months after diagnosis, often due to the side effects of chemotherapy.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoma / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922695.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Kataoka K, Seo S, Sugawara Y, Ota S, Imai Y, Takahashi T, Fukayama M, Kokudo N, Kurokawa M: Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk Lymphoma; 2010 Aug;51(8):1494-501
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature.
  • Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplant.
  • Although living donor liver transplant (LDLT) has been increasingly performed, PTLD after LDLT has not been well investigated.
  • We aimed to determine the clinical characteristics of PTLD after LDLT.
  • We investigated 323 consecutive patients undergoing adult-to-adult LDLT and identified three patients who developed biopsy-proven PTLD.
  • All of them were seropositive for Epstein-Barr virus (EBV) and had hepatitis C virus-related cirrhosis at transplant.
  • All three patients developed late-onset and monomorphic PTLD, including one diffuse large B-cell lymphoma and two Burkitt lymphomas with c-myc rearrangement.
  • The initial therapy included chemotherapy, rituximab, and immunosuppression withdrawal.
  • One patient died of sepsis during treatment and two patients achieved complete responses.
  • We showed a relatively low incidence and distinct clinicopathological features of PTLD after adult-to-adult LDLT, which might reflect the unique nature of LDLT.
  • [MeSH-major] Liver Transplantation / adverse effects. Living Donors. Lymphoproliferative Disorders / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / isolation & purification. Humans. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Review Literature as Topic. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Aug;51(8):1393-4 [20497000.001]
  • (PMID = 20578817.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J: Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer; 2008 Apr;50(4):886-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system.
  • Post-transplant lymphoproliferative disorder (PTLD) in the central nervous system (CNS) has a poor prognosis.
  • New therapeutic approaches should be explored.
  • We report our experience with intrathecal administration of rituximab in a 10-year-old kidney allograft recipient with PTLD in the CNS.
  • After standard treatment had failed, we tried to treat the patient by administering rituximab directly into the cerebral ventricle through an Omaya reservoir, in addition to conventional intrathecal and systemic chemotherapy.
  • Intrathecal administration of rituximab may be a feasible approach in children with PTLD in the CNS.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Kidney Transplantation / adverse effects. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17668865.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


19. Halkos ME, Miller JI, Mann KP, Miller DL, Gal AA: Thoracic presentations of posttransplant lymphoproliferative disorders. Chest; 2004 Dec;126(6):2013-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic presentations of posttransplant lymphoproliferative disorders.
  • BACKGROUND: Posttransplant lymphoproliferative disorders (PTLDs) are rare complications following transplantation.
  • METHODS: Eleven cases of PTLD with a primary thoracic presentation were identified among 3,085 solid-organ transplant patients and 1,662 bone marrow transplant patients from 1990 to 2001.
  • The time to presentation ranged from 1 to 97 months (median time, 8 months).
  • Six patients developed PTLD within 1 year of undergoing transplantation.
  • Pathologic analysis revealed monomorphic PTLD (ie, diffuse large B-cell lymphoma) in seven patients, polymorphic PTLD in two patients, anaplastic large cell lymphoma in one patient, and Hodgkin lymphoma in one patient.
  • All patients were initially treated with a reduction in immunosuppression therapy, and six patients (55%) received adjuvant chemotherapy.
  • Four patients died from complications of PTLD (kidney, two patients; heart, one patient; bone marrow, one patient), and three patients (all lung transplant recipients) died from rejection or infectious complications.
  • CONCLUSIONS: Thoracic PTLD can occur in any transplant patient and must be regarded as a potentially fatal complication in the immunosuppressed patient.
  • Heart and lung allograft recipients have the worst prognosis because of the mortality that accompanies rejection with subtherapeutic immunosuppression therapy.
  • Earlier diagnosis and improvements in immunosuppression and chemotherapy may improve survival for these inherently high-risk patients.
  • [MeSH-major] Lymphoproliferative Disorders / diagnosis. Thoracic Diseases / diagnosis. Transplantation / adverse effects
  • [MeSH-minor] Adult. Antibodies, Viral / analysis. Cytomegalovirus / isolation & purification. Female. Herpesvirus 4, Human / isolation & purification. Humans. Lymphoma / diagnosis. Lymphoma / etiology. Lymphoma / therapy. Lymphoma / virology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15596707.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


20. Yang HY, Ke HY, Hong GJ, Tsai YT, Lin CY, Li CY, Tsai CS: Monotherapy with anti-CD20 monoclonal antibody in a heart transplant recipient with sick sinus syndrome and posttransplantation lymphoproliferative disorder: a case report. Heart Surg Forum; 2009 Oct;12(5):E300-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monotherapy with anti-CD20 monoclonal antibody in a heart transplant recipient with sick sinus syndrome and posttransplantation lymphoproliferative disorder: a case report.
  • Posttransplantation lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation, with an incidence of 0.8% to 20% in heart transplant (HTx) recipients, and standard treatment may be too toxic in some cases.
  • Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies and has been demonstrated effective in combination with chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone).
  • Cardiotoxicity with CHOP remains a major concern for treating HTx recipients with PTLD, however.
  • We present a case of an HTx recipient with sick sinus syndrome and PTLD who was successfully treated with rituximab alone, avoiding the cardiotoxicity of CHOP.
  • The cardiotoxicity induced by CHOP should be kept in mind in HTx recipients with PTLD, especially when there is an existing heart problem in such recipients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Heart Transplantation. Liver Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Postoperative Complications / drug therapy. Sick Sinus Syndrome / complications
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / contraindications. Cyclophosphamide / contraindications. Doxorubicin / contraindications. Graft Rejection / drug therapy. Humans. Immunosuppressive Agents / therapeutic use. Liver / pathology. Male. Middle Aged. Positron-Emission Tomography. Prednisone / contraindications. Rituximab. Tomography, X-Ray Computed. Ultrasonography. Vincristine / contraindications

  • Genetic Alliance. consumer health - Heart Transplant.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833600.001).
  • [ISSN] 1522-6662
  • [Journal-full-title] The heart surgery forum
  • [ISO-abbreviation] Heart Surg Forum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Xu QS, Ye S, Zhou YQ, Sheng JF, Ye K, Zheng SS: Posttransplantation lymphoproliferative disorder involving the central nervous system in liver transplant recipients. Hepatobiliary Pancreat Dis Int; 2008 Oct;7(5):551-4
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplantation lymphoproliferative disorder involving the central nervous system in liver transplant recipients.
  • BACKGROUND: Posttransplantation lymphoproliferative disorder (PTLD) involving the central nervous system (CNS) is a rare and serious complication associated with solid organ transplantation.
  • We treated a case of PTLD with CNS involvement in a liver transplant recipient and reviewed the literature.
  • Craniotomy was performed and PTLD was diagnosed pathologically.
  • The patient was treated with antiviral agents, radiation therapy, and chemotherapy; the immunosuppressive medication was reduced.
  • CONCLUSIONS: Definitive diagnosis of PTLD is only established on the basis of histopathologic evaluation of the tissue.
  • Although there are several ways to manage PTLD with CNS involvement, the prognosis is still poor.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Immunosuppressive Agents / adverse effects. Liver Transplantation / adverse effects. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Antiviral Agents / therapeutic use. Biopsy. Carcinoma, Hepatocellular / surgery. Chemotherapy, Adjuvant. Headache / etiology. Headache / pathology. Humans. Liver Neoplasms / surgery. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18842507.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 13
  •  go-up   go-down


22. Knoop C, Kentos A, Remmelink M, Garbar C, Goldman S, Feremans W, Estenne M: Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission. Clin Transplant; 2006 Mar-Apr;20(2):179-87
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
  • BACKGROUND: Post-transplant lymphoproliferative disorders (PTLD) are potentially lethal complications of solid organ transplantation.
  • We, here, report on our experience with rituximab, an anti-CD20 monoclonal antibody, as first-line treatment for PTLD in six lung transplant recipients.
  • PATIENTS AND METHODS: Two of the patients developed PTLD during the first year after transplantation, while four developed late-onset PTLD.
  • One patient presented with PTLD localized to the graft, one had unilateral cervical lymph nodes, and the others presented with multi-organ involvement.
  • All patients had diffuse large B-cell lymphoma.
  • Immunosuppressive therapy was reduced and rituximab was administered at a dose of 375 mg/m(2)/wk for 4 wk.
  • RESULTS: One patient did not respond to the first two courses of rituximab, received conventional chemotherapy, and achieved complete remission; four patients achieved complete remission after four courses with a median relapse-free survival of 34 months (range: 14-55); and one patient did not respond and died.
  • The diagnosis of complete remission was established by conventional imaging techniques combined to whole-body positron emission tomography scan.
  • CONCLUSIONS: We conclude that reduction in immunosuppression combined to first-line treatment with rituximab may induce long-term complete remission in lung transplant recipients presenting PTLD.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Immunologic Factors / therapeutic use. Lung Transplantation / adverse effects. Lymphoproliferative Disorders / drug therapy. Postoperative Complications / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640524.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


23. Timurağaoğlu A, Uğur-Bilgin A, Colak D, Tuncer M, Gölbaşi I, Hazar V, Kiliçarsłan B, Undar L, Demirbaş A: Posttransplant lymphoproliferative disorders in transplant recipients. Transplant Proc; 2006 Mar;38(2):641-5
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplant lymphoproliferative disorders in transplant recipients.
  • Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation, with a reported incidence between 0.8% and 32%.
  • The incidence of PTLD mainly depends on the transplanted organ, the immunosuppressive drugs, the viral serology, and the age of the recipient.
  • The aim of our study was to analyze our patients diagnosed with PTLD.
  • Among 1040 transplantations, including 931 renal, 14 heart, 55 liver and 40 allogeneic peripheral blood stem cell (PBSC), 8 patients (7 male, 1 female) were diagnosed with PTLD.
  • According to the World Health Organization classification system, six patients were diagnosed as diffuse large B-cell lymphoma, one patient Burkitt's lymphoma, and one polymorphic PTLD.
  • At the time of diagnosis, 7 patients showed positive Epstein-Barr virus (EBV) and cytomegalovirus (CMV) Ig G and negative Ig M; one patient, positive EBV Ig M and negative CMV Ig G and M.
  • One of these patient's pathologic tissue revealed positive EBV DNA, which was not detected in six of the other eight patients.
  • This patient was an 8-year-old boy diagnosed with Burkitt's lymphoma at 31 months after liver transplantation.
  • Seven patients died of disease or complications of chemotherapy.
  • Only one patient survived after the diagnosis of PTLD.
  • In conclusion, even with treatment the mortality rate was high among our patients with PTLD.
  • To decrease the incidence of PTLD and related mortality, risk factors must be evaluated in multicenter studies.
  • [MeSH-major] Lymphoproliferative Disorders / epidemiology. Postoperative Complications / epidemiology. Transplantation Immunology
  • [MeSH-minor] Adult. Child. Female. Heart Transplantation / immunology. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Kidney Transplantation / immunology. Liver Transplantation / immunology. Male. Middle Aged. Stem Cell Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549195.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


24. Choi JH, Park BB, Suh C, Won JH, Lee WS, Shin HJ: Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders. J Korean Med Sci; 2010 Apr;25(4):523-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders.
  • Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoproliferative disorders associated with immunosuppression and Epstein-Barr virus infection.
  • PTLD is classified into three major categories: early lesions, polymorphic PTLD, and monomorphic PTLD.
  • The majority of monomorphic PTLD cases are non-Hodgkin's lymphoma of B-cell origin.
  • This retrospective study was conducted to investigate the incidence, clinical manifestation, treatment, and outcomes of monomorphic PTLD among 5,817 recipients of solid organ or allogeneic hematopoietic stem cell transplantation from five institutions.
  • Fourteen patients with monomorphic PTLD were identified (male:female 11:3; median age 42.6 yr, range 24-60).
  • The most common disease type was diffuse large B cell lymphoma (n=7).
  • The median time between the transplant and diagnosis of PTLD was 85.8 months.
  • However, all cases of PTLD after allogeneic hematopoietic stem cell transplantation occurred within 1 yr after transplantation.
  • Fourteen patients received combination systemic chemotherapy and four patients were treated with radiation therapy.
  • The present study indicates a lower incidence rate and a longer median time before the development of PTLD than those of previous reports.
  • Careful monitoring was needed after allogeneic hematopoietic stem cell transplantation for PTLD.
  • [MeSH-major] Lymphoproliferative Disorders / physiopathology. Transplantation, Homologous / adverse effects
  • [MeSH-minor] Adult. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / immunology. Female. Herpesvirus 4, Human. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):375-85 [10716151.001]
  • [Cites] Blood. 1994 May 1;83(9):2715-22 [8167350.001]
  • [Cites] Bone Marrow Transplant. 2009 Feb;43(4):315-21 [18836488.001]
  • [Cites] Transplantation. 2005 Jan 27;79(2):244-7 [15665775.001]
  • [Cites] Oncologist. 2006 Jun;11(6):674-80 [16794246.001]
  • [Cites] Am J Hematol. 2007 Mar;82(3):208-14 [17022049.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2052-9 [9626203.001]
  • (PMID = 20357991.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2844611
  • [Keywords] NOTNLM ; Monomorphic Post-transplant Lymphoproliferative Disorders
  •  go-up   go-down


25. Muzaffar M, Taj A, Ratnam S: Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab. Am J Ther; 2010 Nov-Dec;17(6):e230-3
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
  • Post transplant lymphoproliferative disease (PTLD) is a rare but potentially fatal complication after solid organ transplantation.
  • The risk of PTLD varies with type of organ transplant, Epstein-Barr virus serostatus of the donor and recipient, age, and intensity of immunosuppression.
  • We report a case of a 45-year-old man who developed aggressive PTLD 7 months after receiving a cadaveric renal transplant.
  • Histopathology revealed Epstein-Barr virus-positive diffuse large B-cell lymphoma with a high mitotic index involving multiple segments of small and large intestines and leading to perforation of the ileum, jejunum, and cecum.
  • The patient had Stage IV disease and treatment consisted of immunosuppression reduction and 375 mg/m rituximab weekly for four doses.
  • There have been very few case reports of PTLD after alemtuzumab induction in renal transplant and the case discussed had simultaneous multiple perforations in the small intestine and colon.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antibodies, Neoplasm / therapeutic use. Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Epstein-Barr Virus Infections / etiology. Fatal Outcome. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Rituximab

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19918163.001).
  • [ISSN] 1536-3686
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Immunosuppressive Agents; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


26. Tang S, Lai KN: Quiz page. Posttransplantation lymphoproliferative disorder (PTLD) involving the brain and the allograft. Am J Kidney Dis; 2005 Apr;45(4):A55, e61-2
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quiz page. Posttransplantation lymphoproliferative disorder (PTLD) involving the brain and the allograft.
  • [MeSH-major] Brain Neoplasms / etiology. Epstein-Barr Virus Infections / complications. Immunosuppression / adverse effects. Kidney Neoplasms / etiology. Kidney Transplantation. Lymphoma, Large B-Cell, Diffuse / etiology. Postoperative Complications / etiology. Transplantation, Homologous / pathology
  • [MeSH-minor] Antilymphocyte Serum / adverse effects. Antilymphocyte Serum / therapeutic use. Cytomegalovirus Retinitis / drug therapy. Cytomegalovirus Retinitis / etiology. Female. Ganciclovir / therapeutic use. Graft Rejection / drug therapy. Herpesvirus 4, Human / isolation & purification. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Middle Aged. Muromonab-CD3 / adverse effects. Muromonab-CD3 / therapeutic use. Mycophenolic Acid / adverse effects. Mycophenolic Acid / analogs & derivatives. Mycophenolic Acid / therapeutic use. Prednisolone / adverse effects. Prednisolone / therapeutic use. RNA, Viral / isolation & purification. Tacrolimus / adverse effects. Tacrolimus / therapeutic use

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806458.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents; 0 / Muromonab-CD3; 0 / RNA, Viral; 9242ECW6R0 / mycophenolate mofetil; 9PHQ9Y1OLM / Prednisolone; HU9DX48N0T / Mycophenolic Acid; P9G3CKZ4P5 / Ganciclovir; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down






Advertisement